Category: Artificial Intelligence

Explore our library of blogs, insights, research papers, and more information on compliance in the life sciences industry.

The 3rd Annual Global Compliance Congress for Life Sciences was held by the CBI at the Hilton London Olympia on the 16th & 17th of November, 2016. The conference provided an excellent platform for representatives of life sciences companies to network, share ideas and learn from one another. The ambiance at the conference was high-energy […]

For most pharma companies in the EU, seeking the consent of the HCP’s/HCO’s that they indulge in transactions is the most appropriate means of ensuring compliance with data protection laws when disclosing their spending under the EFPIA disclosure code. Indeed, the Code comes with guidance notes that place special emphasis on pharmaceutical companies seeking consent […]

As the reporting date under the US Sunshine Act approaches, compliance teams are working harder than ever to collect spend records and have them audited and ready to submit to CMS. If anything, the frenzy of resolving system issues, vendor management, and personnel challenges makes it extremely hard for most compliance teams to reach the […]

Clinical practices, at least the very best of them, take place out in the open. If anything, these depend on the expertise and input from several groups like academics, clinicians, healthcare organizations, manufacturers of medicines and medical technology, and even patient organizations. These collaborations, however, need to be transparent, and for this particular purpose, the […]

The 17th Annual Pharma and Medical Device Compliance Congress was held at the Mandarin Hotel in Washington, D.C from the 19th to the 21st of October, 2016. The conference provided an excellent opportunity for senior representatives from the compliance, legal, transparency, legal affairs, commercial operations/marketing, and regulatory affairs industries to network and discuss operational best […]

With the government taking a more proactive approach to mining Open Payments data to evaluate, investigate, and detect cases of healthcare fraud, pharmaceutical companies are even more keen to proactively stamp out any suspicion of fraud proactively, and they are turning to analytics techniques to do so. No pharma company wants to find out second […]